KPTI (Karyopharm Therapeutics) Beta: 2.0403 (As of Jul. 01, 2026)


KPTI Karyopharm Therapeutics Inc KPTI
52 GF Score
Price $9.76
GF Value $6.39
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Karyopharm Therapeutics Beta?

Karyopharm Therapeutics KPTI -3.17% 52 Beta is 2.0403 as of Jul. 01, 2026. GuruFocus rates KPTI with a GF Score™ of 52/100 and a GF Value™ of $6.39 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-01), Karyopharm Therapeutics's Beta is 2.0403.


Karyopharm Therapeutics  (NAS:KPTI) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Karyopharm Therapeutics Beta Related Terms


Karyopharm Therapeutics Beta Historical Data

* Premium members only.

The historical data trend for Karyopharm Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Karyopharm Therapeutics Beta Chart

Karyopharm Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.63 -0.32 -0.25 0.51 1.38

Karyopharm Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.37 0.76 1.63 1.38 1.55

KPTI vs CHRS, TARA, CNTN: Beta Comparison

For the Biotechnology subindustry, Karyopharm Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karyopharm Therapeutics Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Karyopharm Therapeutics's Beta falls into.


KPTI
52GF Score
Karyopharm Therapeutics Inc KPTI
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Karyopharm Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 2.0403 mean?
Karyopharm Therapeutics (KPTI) has a Beta of 2.0403 as of Jul. 01, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Karyopharm Therapeutics and its competitors.
Is Karyopharm Therapeutics' Beta too high?
Karyopharm Therapeutics' current Beta is 2.0403. Overall, Karyopharm Therapeutics has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Karyopharm Therapeutics' Beta compare to CHRS and TARA?
Karyopharm Therapeutics' Beta of 2.0403 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Karyopharm Therapeutics and its competitors. Karyopharm Therapeutics's current Beta is 2.0403. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Karyopharm Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Karyopharm Therapeutics (KPTI) is currently considered Significantly Overvalued. The stock's GF Value™ is $6.39, compared to a current price of $9.76 — trading 52.7% above its estimated fair value. The current Beta is 2.0403. Karyopharm Therapeutics' overall GF Score™ is 52/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Karyopharm Therapeutics (KPTI), the current Beta is 2.0403 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Karyopharm Therapeutics (KPTI) Overvalued in 2026?

Based on GuruFocus' analysis, Karyopharm Therapeutics stock appears to be overvalued. The current stock price of $9.76 is trading 52.7% above its estimated GF Value™ of $6.39. GuruFocus considers Karyopharm Therapeutics to be Significantly Overvalued.

Key valuation signals for KPTI:

  • Beta: 2.0403
  • GF Value™: $6.39 vs. price of $9.76 (52.7% above fair value)
  • GF Score™: 52/100 with 8 warning signs

No single metric tells the full story. See the KPTI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Karyopharm Therapeutics Business Description

Other Exchanges 25K0:Germany
Address 85 Wells Avenue, 2nd Floor, Newton, MA, USA, 02459
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
52GF Score

Get the complete analysis for KPTI

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$9.76
Price
$6.39
GF Value